50Real-world characteristics and outcomes of durvalumab + gemcitabine + cisplatin in patients with cholangiocarcinoma in the US
The Oncologist · 2026-06-01
52Treatment patterns among patients with extrahepatic cholangiocarcinoma with autoimmune conditions: a retrospective study
The Oncologist · 2026-06-01
53Treatment outcomes of patients with mIDH1 cholangiocarcinoma in the United States
The Oncologist · 2026-06-01
Abstract CT164: A phase II trial of cabozantinib with atezolizumab in refractory, metastatic pancreatic adenocarcinoma
Cancer Research · 2026-04-17
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Nature Medicine · 2026-04-14 · 2 citations
Abstract LB-A002: Open-label, Phase Ib dose-expansion study assessing the efficacy of the CD137/FAP agonist BI 765179 plus pembrolizumab as first-line therapy in metastatic or incurable, recurrent PD-L1-positive head and neck squamous cell carcinoma
Cancer Immunology Research · 2026-03-05
Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B phase 2 study.
Journal of Clinical Oncology · 2026-01-10
Subgroup analyses from the phase 3 PANOVA-3 trial of tumor treating fields (TTFields) with gemcitabine/nab-paclitaxel in locally advanced pancreatic adenocarcinoma: Efficacy and safety by sex, age, and body mass index (BMI).
Journal of Clinical Oncology · 2026-01-10
Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
Journal of Clinical Oncology · 2026-01-10
Treatment outcomes of patients with m <i>IDH1</i> cholangiocarcinoma in the United States.
Journal of Clinical Oncology · 2026-01-10
Decoding molecular, clinico-pathological, and outcome differences between early-onset (EO, <50 years) and late-onset (LO, ≥50 years) mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC): Insights from real-world data.
Journal of Clinical Oncology · 2026-01-10
Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025-12-01
Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025-12-01
Supplementary Data 1 from Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC
2025-11-25
ACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer
Journal of the American College of Radiology · 2025-11-01 · 1 citations
Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Nature Communications · 2025-09-30 · 34 citations
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
Clinical Cancer Research · 2025-09-30 · 6 citations
Multi-omic characterization of early-onset esophagogastric cancer
npj Precision Oncology · 2025-07-17 · 2 citations
410P Comprehensive molecular and immunological characterization of CLDN18.2 in esophageal and esophagogastric junction carcinoma (EEJC)
Annals of Oncology · 2025-07-01 · 1 citations
344P Patient characteristics, molecular testing, and treatment patterns of patients with cholangiocarcinoma in the United States: Focus on mIDH1 patients
Annals of Oncology · 2025-07-01